HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Regulation/Legislation (Health)

Set Alert for Regulation {Health}


Set Alert for Regulation {Health}

Latest From Health & Regulation

IND Warning Has US Supplement Firm ISO Answers

RAAS Nutritionals tells FDA “it proceeded without an IND because it believed that if it was legally able to sell its nutritional supplements ... it should be able to test and observe the effects of those supplements without an IND.”

Warning Letters Dietary Supplements

US FDA Warns Of Safety Risk OTC Needle-Free Devices Used For Dermal Fillers

Agency safety communication says needle-free dermal filler “pens” sold OTC on social media could pose a serious risk to consumers. It's aware of serious injuries, including  permanent harm to skin, lips, or eyes with the use of needle-free devices for injection of lip and facial fillers.

FDA OTC Devices

Real-World Evidence Can Play Important Role In OTC Regulation – AESGP Study

A published article from AESGP argues for the increased acceptability, application and use of real-world evidence in the OTC sector where it “may present a more intuitive or efficient way of generating data” compared to randomized controlled trials.

Real-World Evidence OTC Drugs
See All


Set Alert for Legislation {Health}

Latest From Health & Legislation

US OTC Monograph FY2022 Facility Fees Deadline In June At Amount TBD

Firms making OTC monograph drugs won’t have to pay facility fees twice during FY2021, says Theresa Michele, FDA Office of Nonprescription Drugs director.

User Fees OTC Drugs

US FDA Meets Initial Deadlines In OTC Monograph Overhaul While It's Rebuilding The Program

Authorization was a long time coming for FDA to reform OTC monograph program and streamline process to change formulations, indications or labeling for large majority of drugs available nonprescription. As program is overhauled, monograph updates may seem to be coming just as slowly.

FDA Legislation

Protecting US Consumer Data Just The Tip Of Online Privacy Iceberg, Says FTC’s Slaughter

At NAD conference, Commissioner Slaughter identified “erroneous points of conventional wisdom that tend to undergird legal and policy debate about digital surveillance,” starting with privacy being “the key issue” and including “the FTC is toothless, absent new federal legislation.”

Ad Complaints Enforcement
See All